Literature DB >> 31959893

Sinusoidal obstruction syndrome: a warning about autologous stem cell transplantation preceded by regimens containing oxaliplatin.

Pierre-Edouard Debureaux1, Delphine Le Febvre de Nailly2, Emmanuelle Tavernier3, Manel Bedoui4, Frederique Kuhnowski4, Jerome Tamburini5, Luc-Matthieu Fornecker6, Vincent Camus7, David Sibon8, Marie-Pierre Moles9, Sylvie Glaisner10, Jean Philippe Richardet11, Sebastien Mule12,13, Julien Calderaro14, Daniel Azoulay15, Jehane Fadlallah16, Corinne Haioun17,13, Jehan Dupuis17.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 31959893     DOI： 10.1038/s41409-020-0796-6

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN： 0268-3369            Impact factor:   5.483


× No keyword cloud information.
  3 in total

1.  Sinusoidal obstruction syndrome/veno-occlusive disease complication in lymphoma patients treated with oxaliplatin-based regimen: A case series report.

Authors:  E Bernichon; E Daguenet; C Molla; J Cornillon; C Lejeune; F Casteillo; D Guyotat; E Tavernier
Journal:  Curr Res Transl Med       Date:  2018-03-05       Impact factor: 4.513

2.  Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party.

Authors:  E Carreras; H Bertz; W Arcese; J P Vernant; J F Tomás; H Hagglund; G Bandini; H Esperou; J Russell; J de la Rubia; G Di Girolamo; H Demuynck; O Hartmann; J Clausen; T Ruutu; V Leblond; A Iriondo; A Bosi; I Ben-Bassat; V Koza; A Gratwohl; J F Apperley
Journal:  Blood       Date:  1998-11-15       Impact factor: 22.113

3.  Granulocyte colony-stimulating factor increases expression of adhesion receptors on endothelial cells through activation of p38 MAPK.

Authors:  Berta Fusté; Roberto Mazzara; Ginés Escolar; Anna Merino; Antonio Ordinas; Maribel Díaz-Ricart
Journal:  Haematologica       Date:  2004-05       Impact factor: 9.941
  3 in total
  1 in total

1.  Ibrutinib Associated with Rituximab-Platinum Salt-Based Immunochemotherapy in B-Cell Lymphomas: Results of a Phase 1b-II Study of the LYSA Group.

Authors:  Christophe Bonnet; Jehan Dupuis; Hervé Tilly; Thierry Lamy; Christophe Fruchart; Steven le Gouill; Catherine Thieblemont; Franck Morschhauser; Olivier Casasnovas; Krimo Bouabdallah; Hervé Ghesquieres; Eric Van Den Neste; Marc André; Guillaume Cartron; Gilles Salles
Journal:  Cancers (Basel)       Date:  2022-03-30       Impact factor: 6.575
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.